Last reviewed · How we verify

NCT04989062

Predicting Obesity Consequences Using Body Measure and Urine Metabolomics

Status unknown Last updated 4 August 2021
What this trial tests

trial testing Fibroscan in Non-Alcoholic Fatty Liver Disease in 1,200 participants. Status unknown.

Timeline
1 August 2020
Primary endpoint
31 July 2022
31 July 2022

Quick facts

Lead sponsorChang Gung Memorial Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment1,200
Start date1 August 2020
Primary completion31 July 2022
Estimated completion31 July 2022
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Chang Gung Memorial Hospital

Who can join

Adults 6 to 13, any sex, with Non-Alcoholic Fatty Liver Disease or Body Composition. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective observational study which will recruit up to 1200 participants over a two-year period to investigate whether non-invasive methods such as bioelectrical impedance analysis parameters and urine metabolic profile are predictors for pediatric non-alcoholic liver disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Fibroscan

Trials testing the same drug.

Other recruiting trials for Non-Alcoholic Fatty Liver Disease

Currently open trials in the same condition.

Other Chang Gung Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04989062.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing